Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Cash from Operations (2020 - 2025)

Historic Cash from Operations for Cytek Biosciences (CTKB) over the last 6 years, with Q3 2025 value amounting to -$3.9 million.

  • Cytek Biosciences' Cash from Operations fell 12948.34% to -$3.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.9 million, marking a year-over-year decrease of 10583.09%. This contributed to the annual value of $25.4 million for FY2024, which is 38057.19% up from last year.
  • As of Q3 2025, Cytek Biosciences' Cash from Operations stood at -$3.9 million, which was down 12948.34% from $108000.0 recorded in Q2 2025.
  • Over the past 5 years, Cytek Biosciences' Cash from Operations peaked at $13.2 million during Q3 2024, and registered a low of -$9.4 million during Q2 2022.
  • In the last 5 years, Cytek Biosciences' Cash from Operations had a median value of $1.2 million in 2021 and averaged $1.0 million.
  • As far as peak fluctuations go, Cytek Biosciences' Cash from Operations plummeted by 74633.94% in 2022, and later soared by 41188.96% in 2024.
  • Over the past 5 years, Cytek Biosciences' Cash from Operations (Quarter) stood at $5.4 million in 2021, then increased by 13.67% to $6.2 million in 2022, then soared by 53.59% to $9.5 million in 2023, then tumbled by 79.01% to $2.0 million in 2024, then plummeted by 295.19% to -$3.9 million in 2025.
  • Its last three reported values are -$3.9 million in Q3 2025, $108000.0 for Q2 2025, and -$125000.0 during Q1 2025.